Catalyst Wire Dossier Catalyst Wire Dossier

ORA3 (peroral insulin in dextran matrix)

insulin · Bows Pharmaceuticals AG
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ORA3 (peroral insulin in dextran matrix), covering 2010-10-05 to 2010-10-05. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Determine the Absorption of Peroral Insulin in Dextran Matrix (ORA3) [Phase 1]

See pricing